504 related articles for article (PubMed ID: 28221220)
1. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
2. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
3. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
4. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
[TBL] [Abstract][Full Text] [Related]
5. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
[TBL] [Abstract][Full Text] [Related]
6. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
Fleshner K; Carlsson SV; Roobol MJ
Nat Rev Urol; 2017 Jan; 14(1):26-37. PubMed ID: 27995937
[TBL] [Abstract][Full Text] [Related]
7. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
[TBL] [Abstract][Full Text] [Related]
8. What's new in screening in 2015?
Carlsson SV; Roobol MJ
Curr Opin Urol; 2016 Sep; 26(5):447-58. PubMed ID: 27326657
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
[TBL] [Abstract][Full Text] [Related]
10. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
11. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
12. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update.
Vetterlein MW; Dalela D; Sammon JD; Karabon P; Sood A; Jindal T; Meyer CP; Löppenberg B; Sun M; Trinh QD; Menon M; Abdollah F
Urology; 2018 Feb; 112():56-65. PubMed ID: 29056579
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
[TBL] [Abstract][Full Text] [Related]
15. Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
Joshi SS; Filson CP
Cancer; 2020 Feb; 126(4):694-696. PubMed ID: 31794066
[No Abstract] [Full Text] [Related]
16. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
17. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
18. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
19. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
Li J; Berkowitz Z; Hall IJ
J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
[TBL] [Abstract][Full Text] [Related]
20. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]